News Feature

Filter By:

Article Type
  • Oncology remains the most active area for dealmaking; in 2018, projected deal values increased substantially, driven by deals in immuno-oncology, and a number of major mergers and acquisitions were announced. In this feature, authors at Clarivate Analytics explore the trends in recent oncology deals.

    • Helen Dowden
    • Jamie Munro
    News Feature
  • We bring together recent therapy and technology features, based upon some of February's largest biopharma deals.

    • Raveena Bhambra
    News Feature
  • We bring together recent therapy and technology features, based upon some of January's largest biopharma deals.

    • Raveena Bhambra
    News Feature
  • From the $59 billion Shire acquisition by Takeda, to the $800 million that United Therapeutics paid upfront for Arena’s pulmonary arterial hypertension drug candidate ralinepag, 2018 was a year punctuated by product and company valuations that sometimes seemed out of sync with reality. Evaluate's Jon Moser and Paul Verdin explore the landscape of high-value unpartnered assets.

    • Raveena Bhambra
    News Feature
  • Continuing our dealmaking series, we explore one of the initial stages—finding a suitable partner—and provide advice on attracting and selecting the right match for your company and products.

    • Biopharma Dealmakers
    News Feature
  • Early-stage developments are attracting investment and driving dealmaking within the challenging neuroscience field, particularly for pain and Alzheimer’s disease, as the industry aims to move past the many late-stage clinical failures in recent years.

    • Jamie Munro
    • Helen Dowden
    News Feature
  • Against the backdrop of a very deep and broad pipeline, the next breakthroughs in the immuno-oncology space will hinge on leveraging partnerships to improve existing therapies and to develop new strategies.

    • Gaspar Taroncher-Oldenburg
    News Feature
  • As a result of the recent landmark gene therapy and chimeric antigen receptor T cell approvals, momentum is building in the field of regenerative medicine. Increased funding and regulatory support has brought confidence to developers that are now bringing a new generation of concepts to the clinic.

    • Cormac Sheridan
    News Feature
  • The market for drugs and vaccines to combat infectious diseases is expanding overall, but with wide variation in sales among its segments. This article analyzes the products, trends and dealmaking underlying these changes.

    • Antonio Iervolino
    News Feature
  • Fibrosis-related diseases, such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis, have generated a wave of deal and funding activity over recent years. Here, we highlight a selection of these deals.

    News Feature
  • Inadequate or unsuitable intellectual property (IP) protection could allow competitors to more easily launch a competing product, jeopardizing the opportunity for meaningful return on investment and consequently potential dealmaking. This feature discusses key factors for biotechnology companies to consider in creating IP strategies to support value.

    • Isobel Finnie
    News Feature
  • Although dealmaking in the medtech industry slowed in 2017, political developments and innovations in areas such as digital health technologies could fuel greater activity in 2018.

    • Amanda Micklus
    • Maureen Riordan
    News Feature
  • In a week that was relatively quiet for dealmaking compared to many others this year, there were still two high-value deals in the CNS space, which continues to generate deals and funding despite recent clinical failures in the area.

    • Raveena Bhambra
    News Feature
  • We’ve returned to review the leading deals in biopharma after a spring break. Whilst we were away a number of significant deals took place.

    • Raveena Bhambra
    News Feature
  • Last week saw two major deals in neuroscience, supporting analysts’ optimism about the field, despite Pfizer’s recent exit.

    • Raveena Bhambra
    News Feature